Family carers/caregivers of people living with dementia Mental and Behavioural Disorders
Conditions
Interventions
Randomisation to treatment arm will take place after consent and baseline data have been collected. The randomisation scheme will be computer-generated by the Clinical Trials Unit data manager. This w
Sponsors
University of Exeter
Eligibility
Sex/Gender
All
Age
18 Years to 100 Years
Inclusion criteria
Inclusion criteria: 1. Currently care/support (e.g., informally, unpaid*) for a person living with dementia (may be a partner, family member, in-law, close friend or neighbour) 2. The person living with dementia (all subtypes) has been diagnosed within the last 5 years 3. 18 years or over 4. Living in the UK 5. Access to a device with a camera and microphone which connects to the internet (e.g., laptop, tablet, smartphone) 6. Seeking to learn new skills and knowledge to cope well while caring for a person living with dementia 7. Able to engage in and understand the programme delivered in English (with the help of a family interpreter if required) *Family carers claiming carer’s allowance are not excluded
Exclusion criteria
Exclusion criteria: 1. Potential participants with insufficient cognitive abilities to engage with the online programme 2. Potential participants who report feeling overburdened 3. The person living with dementia currently resides in a care home 4. Taking part or recently taken part in a research study using a similar behaviour change or psychological intervention 5. Taken part in CareCoach (Work Package 3) feasibility study (ISRCTN12540555) 6. Is a paid, professional carer Multiple members of the same family (e.g., individuals caring for the same person living with dementia) should not sign up for the trial to avoid potential contamination between groups
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Carer self-efficacy symptom management in the Caregiver Self-Efficacy Scale (CSES) at 6 months post-randomisation | — |
Secondary
| Measure | Time frame |
|---|---|
| Clinical outcomes (carers only): 1. Self-efficacy for symptom management is measured using CSES at 10 weeks post-randomisation 2. Self-efficacy for community support service use is measured using CSES at baseline, 10 weeks post-randomisation, and 6 months post-randomisation 3. Mastery is measured using the Pearlin Mastery Scale (PMS) at baseline, 10 weeks post-randomisation, and 6 months post-randomisation 4. Impact of dementia on carers is measured using SIDECAR-D at baseline, 10 weeks post-randomisation, and 6 months post-randomisation 5. Perceived stress is measured using the Perceived Stress Scale (PSS) at baseline, 10 weeks post-randomisation, and 6 months post-randomisation 6. Anxiety is measured using the Generalised Anxiety Disorder Scale (GAD-7) at baseline, 10 weeks post-randomisation, and 6 months post-randomisation 7. Depression is measured using the Patient Health Questionnaire (PHQ-9) at baseline, 10 weeks post-randomisation, and 6 months post-randomisation 8. Health-related quality of life is measured using EQ-5D-5L at baseline, 10 weeks post-randomisation, and 6 months post-randomisation Cost-effectiveness outcomes: 9. Carer-rated proxy health-related quality of life of the person living with dementia is measured using EQ-5D-5L at baseline, 10 weeks post-randomisation, and 6 months post-randomisation 10. Service use is measured using the Modified Client Service Receipt Inventory (CSRI) at baseline and 6 months post-randomisation | — |
Countries
England, United Kingdom
Contacts
Public ContactHelen Morse
Outcome results
None listed